The antibodies MRK16 and MRK17 inhibited Abcb1-mediated efflux in vitro and in animal tumor models and increased doxorubicin efficacy (Broxterman et al., 1988; Tsuruo et al., 1989; Mechetner and Roninson, 1992). Here, ABCB1 is linked to neoplasm.